As expected, our findings confirm overall higher mutational burden in the metastatic setting, with several key driver genes being significantly more mutated as compared to early stage breast cancer (ESR1, KMT2C, MAP3K1, PTEN, CASP8, EGFR, AKT1, ATM, and RB1) (S3 Fig). The gene discussed is AKT1; the disease is breast cancer.